Key Takeaways

Berberine’s full therapeutic potential can be realized by developing a more bioavailable form which is needed to overcome its poor intestinal absorption and avoid occurrences of gastrointestinal distress due to higher administered dosages.

  • LipoVantage® Liposomal Berberine demonstrated significantly greater Cmax and AUC0-24 compared to non-liposomal berberine placebo (p=0.03).
  • LipoVantage® Liposomal Berberine had significantly higher Cmax (+70.1%, p=0.03) and AUC0-24 (+42.8%, p=0.03) values as compared to non-liposomal berberine.

LipoVantage® Liposomal Delivery Significantly Enhances the Absorption of Berberine

In a randomized, double-blind, crossover study design, subjects ingested a single dose of 1,000 mg of unformulated berberine, or 1,000 mg of LipoVantage® liposomal berberine. Venous blood samples were collected after ingestion and analyzed for plasma berberine concentrations. Results shows that LipoVantage® liposomal berberine demonstrated significantly greater Cmax and AUC0-24 compared to non-liposomal berberine placebo (p=0.03). Additionally, LipoVantage® liposomal berberine had significantly higher Cmax (+70.1%, p=0.03) and AUC0-24 (+42.8%, p=0.03) values as compared to non-liposomal berberine. No differences between groups were observed for 24-hour changes for metabolic and safety markers.

Purpura M, Jäger R, Godavarthi A, Ceylan Hİ, Chandrappa A, Tinsley GM. Liposomal Delivery as a Strategy to Improve Berberine Bioavailability: A Double-Blind, Crossover, Randomized Pilot Study in Healthy Males. Nutrition and Dietary Supplements. 2026;18:1-13